Three supply chain opportunities for the healthcare sector
Ray Berglund and Lee Feander, leaders in Alvarez & Marsal’s Healthcare practice, share three supply chain opportunities for the healthcare sector in the post-Covid-19 era.
1. Remote Patient Monitoring
The telehealth market grew at a phenomenal rate in 2020 (around 60% in the US) as Covid-19 disrupted healthcare. Telehealth is projected to grow at a CAGR of around 40% through to 2025.
Remote patient monitoring (RPM) is a fast-growing telehealth sub-sector involving the collection, transmission, evaluation and communication of patient health data from a range of electronic devices including wearable sensors, implanted equipment and handheld instruments.
RPM technologies have already been applied to collect vital signs of Covid-19 patients at Mount Sinai Health System in New York City and University Hospitals in Cleveland, Ohio. The Mayo Clinic in Minnesota is setting up remote monitoring for patients with non-COVID conditions such as congestive heart failure.
There is a compelling case for RPM post-Covid-19, where success for pharma firms, medtech companies and other service providers will depend on managing increased complexity along supply chains in terms of technologies, data, processes and systems.
For example, patient level demand signals could be obtained from many devices, requiring upgrades to processes and IT systems. Value generated must be shared equitably with participating parties, including reimbursement and contracts. Change management to support adoption will play a critical role, and should be included in cross-organisation transformation plans.
Investors must correctly judge the operational advantages and commercial potential of these innovations. In terms of operations, an understanding of the data, systems and IT tools will be vital along with a view on capabilities and scalability. On the commercial side, patient needs, market size and growth and the competitive landscape all need to be intimately understood.
2. Direct-to-patient distribution
Although home deliveries are not yet part of the healthcare mainstream, Covid-19 has accelerated providers’ and patients’ appetites for direct-to-patient models. Whether in trials or for recurring prescriptions, direct-to-patient models promise considerable benefits for patients. Not only are they much more convenient, they also reduce waste and improve adherence to dose recommendations and regimes, as only what is needed is shipped.
Pharma manufacturers benefit in terms of better visibility of demand, plus deeper insights on patient requirements. Manufacturers can capture margins previously charged by wholesalers, and prices can be set based on channel. In addition, parallel imports can be controlled since ownership remains with pharmaceutical companies (direct-to-patient models are particularly relevant for biologics and cell and gene therapies where the cost of distribution is small relative to the treatment cost).
Regulation must also be reviewed to understand what is legal in terms of home deliveries. Proactive engagement with health ministries is helpful; at present, there may be more willingness to challenge traditional approaches as a result of the Covid-19 crisis.
For investors there are a number of innovative companies offering specialised home delivery services, such as Healthcare at Home, PantherX, Viela Pharmaceuticals and Polarspeed, as well as related businesses such as cold chain shippers (Evo, Polar Thermal) and temperature monitoring systems (Berlinger, TempTracer). It will be important to determine the total customer base needed for economic service delivery.
While direct-to-patient can deliver margin improvements by avoiding wholesalers, the costs of service delivery need to be carefully assessed relative to the value of medicines being delivered, plus any nursing support.
3. Supply chain resilience
An increased level of patient engagement must be supported by resilient, high-performing supply chains. Otherwise, stock-outs or late deliveries would make these solutions at best meaningless and at worst damaging to patient health.
Manufacturers should consider alternative sourcing where possible. Already some supply chain activities (raw materials and product manufacturing) are shifting from China to India due to the US/China trade war. We envisage Covid-19 will accelerate this trend for resilience and alternative supply reasons.
Reliable assessment of Contract Manufacturing Organisations (CMOs) including quality, cost and delivery performance, and ability to scale, will be important. Ramping up of new CMOs will need robust technical transfer management to mitigate supply risks.
In terms of planning, manufacturers should look to supplement sales and operational planning with data from RPM technologies and direct-to-patient logistics providers. Planning meetings and decision-making processes ought to be upgraded to consider the new channels. Existing ERP software such as Kinaxis or SAP may need to be expanded and made fit for the future.
Pharmaceutical manufacturers have been dealing with wider product ranges and smaller volumes for many years. This trend will continue, for instance with personalised medicines having ‘vein-to-vein’ supply chains (where tissue or blood is taken from a patient and medicine is manufactured to their specific requirements, then administered to the same patient), and much greater complexity (eg. very short shelf-lives, different temperature regimes, high demand volatility).
For these products, supply chain orchestration is very important, encompassing patient engagement, care management, health outcomes, funds and data management. Companies such as Trackcell and Vinetti provide personalised therapy management platforms covering these areas.
We also expect postponement models to become more prevalent. In a postponement model, products are held in semi-finished states and finalised (often labelling and packaging) on customer demand. Lean production methods, including rapid quality checks, typically support final stages of postponement. A number of logistics providers can perform postponement, or manufacturers can do themselves. The choice depends on complexity, capabilities and risk appetite.
Finally, while in-market distribution will largely be governed by direct-to-patient providers, intercompany distribution may have scope for rationalisation of logistics service providers, particularly if they can provide postponement and in-market services.
Ray Berglund is a managing director and Lee Feander a senior director at Alvarez & Marsal’s Healthcare practice.
